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Summary. Background: Platelet activationby collagendepends
on signals transduced by the glycoprotein (GP)VI–Fc receptor
(FcR)c-chain collagen receptor complex,which involves recruit-
ment of phosphatidylinositol 3-kinase (PI3K) to phosphory-
lated tyrosines in the linker for activation of T cells (LAT). An
interaction between the p85 regulatory subunit of PI3K and the
scaﬀolding molecule Grb-2-associated binding protein-1
(Gab1), which is regulated by binding of the Src homology 2
domain-containing protein tyrosine phosphatase-2 (SHP-2) to
Gab1,hasbeen shown inother cell types to sustainPI3Kactivity
to elicit cellular responses. Platelet endothelial cell adhesion
molecule-1 (PECAM-1) functions as a negative regulator of
platelet reactivity and thrombosis, at least in part by inhibiting
GPVI–FcRc-chain signaling via recruitment of SHP-2 to
phosphorylated immunoreceptor tyrosine-based inhibitory
motifs in PECAM-1. Objective: To investigate the possibility
that PECAM-1 regulates the formation of the Gab1–p85
signaling complexes, and thepotential eﬀect of such interactions
onGPVI-mediatedplatelet activation inplatelets.Methods:The
ability of PECAM-1 signaling to modulate the LAT signalo-
some was investigated with immunoblotting assays on human
platelets and knockout mouse platelets. Results: PECAM-1-
associated SHP-2 in collagen-stimulated platelets binds to p85,
which results in diminished levels of associationwith bothGab1
and LAT and reduced collagen-stimulated PI3K signaling. We
therefore propose that PECAM-1-mediated inhibition of
GPVI-dependent platelet responses result, at least in part, from
recruitment of SHP-2–p85 complexes to tyrosine-phosphory-
latedPECAM-1,whichdiminishes the associationof PI3Kwith
activatory signaling molecules, such as Gab1 and LAT.
Keywords: GPVI, inhibitory, ITIM, PECAM-1, signaling.
Introduction
Platelet endothelial cell adhesion molecule-1 (PECAM-1,
CD31) is a 130-kDa membrane-spanning glycoprotein (GP)
that belongs to the immunoglobulin (Ig) family of cell adhesion
molecules and consists of a 574-residue extracellular domain
composed of six Ig-like homology domains, a 19-residue
transmembrane domain, and an 118-residue cytoplasmic tail
[1–3]. PECAM-1 is expressed on the surfaces of endothelial
cells and several hematopoietic cell types, including platelets,
megakaryocytes, monocytes, neutrophils, natural killer cells,
and naı¨ve subsets of T and B cells [4,5].
PECAM-1 is a signaling molecule that plays diverse roles in
vascular biology, including modulation of platelet function [6–
9], angiogenesis [10], vasculogenesis [11], integrin regulation
[12,13], T-cell and B-cell activation [14,15], and mediation of
leukocyte migration across the endothelium [16,17]. This
receptor also plays an important role in the inhibition of both
systemic and tissue-speciﬁc inﬂammatory responses [18–20],
and, more recently, has been implicated in both proathero-
sclerotic and atheroprotective effects, inﬂuencing the initiation
and progression of atherosclerosis [21,22].
In platelets, we and others have shown that clustering or
ligation of PECAM-1 inhibits signal transduction by the
activatory collagen receptor GPVI, which hinders platelet
aggregation and thrombus formation [8,9], although the
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mechanism for this inhibitory effect remains to be established.
The inhibition of GPVI-stimulated platelet activation by
PECAM-1 is associated with diminished protein tyrosine
phosphorylation and decreased calcium mobilization [7]. We
have found, however, that early tyrosine kinase-dependent
signaling, including phosphorylation of the Fc receptor
(FcR)c-chain, spleen tyrosine kinase (Syk) and linker for
activation of T cells (LAT), following stimulation of GPVI is
largely unaffected by stimulation of PECAM-1 (data not
shown). In this study, we therefore explored the next steps
downstream, coordinated through the assembly of the LAT
signalosome. Upon homophilic ligation and antibody-medi-
ated clustering or following stimulation with collagen or
thrombin, PECAM-1 becomes tyrosine-phosphorylated by
Src-family kinases [6,23,24]. PECAM-1 also becomes tyrosine-
phosphorylated following activation and aggregation of plate-
lets, which is proposed to represent a negative feedback
mechanism [6,7,23]. The cytoplasmic tail of human PECAM-1
has two distinct immunoreceptor tyrosine-based inhibitory
motifs (ITIMs) surrounding tyrosines at positions 663 and 686
[25]. These ITIMs can serve as docking sites for signaling
molecules such as non-receptor Src homology 2 (SH2) domain-
containing protein tyrosine phosphatase-2 (SHP-2), which
binds to the phosphorylated ITIMs through tandem SH2
domain-dependent interactions [26,27]. Several reports have
strongly implicated SHP-2 in the functions of PECAM-1 in
several cell systems [15,23,24,28,29].
SHP-2 is involved in the signaling pathways of a variety of
growth factor-initiated and cytokine-initiated signal trans-
duction processes, thereby regulating a range of cellular
responses [30–33]. Although protein tyrosine phosphatases act
to counter the effects of tyrosine kinase-dependent pathways,
SHP-2, in most circumstances, plays a positive regulatory role
in signal transduction, as previously reported for the regula-
tion of growth factor receptor signaling [34]. Previous studies
have demonstrated that a number of signaling proteins, such
as Grb2, the p85 subunit of phosphatidylinositol 3-kinase
(PI3K), and Grb2-associated binding protein 1 (Gab1),
associate with SHP-2 after cytokine and growth factor
receptor activation, leading to enhanced signal transduction
[35]. Gab1 belongs to a family of scaffolding adaptor proteins,
which have an N-terminal pleckstrin homology domain,
multiple tyrosine-based motifs, and proline-rich sequences
[36,37]. Upon growth factor, cytokine and antigen receptor
stimulation, Gab1 provides a number of docking sites to
mediate interactions with SH2 domain-containing proteins,
such as SHP-2 and the p85 subunit of PI3K, mediating
intracellular responses. Given the physiologic importance of
the Gab1–SHP-2 association, it has been suggested that a
primary role of Gab1 is to recruit SHP-2 [38]. Furthermore,
SHP-2 regulates the amount of p85 that is bound to Gab1 by
dephosphorylating p85-binding sites on Gab1 [38]. The
physical association between p85 and Gab1 is important in
mediating the PI3K signaling pathway induced by growth
factors [37]. In this way, SHP-2 negatively regulates theGab1–
p85 interaction, controlling the kinetics and reducing the
extent of PI3K signaling following epidermal growth factor
stimulation [38].
LAT is an adaptor molecule that, upon phosphorylation by
Syk, nucleates the formation of a protein complex that enables
recruitment and activation of phospholipase C (PLC)c2
following GPVI stimulation [39,40]. The activation of PLCc2
in response to GPVI stimulation depends on recruitment of
PI3K to phosphorylated LAT via the SH2 domains of the p85
subunit. Once recruited to the plasma membrane, PI3K
phosphorylates phosphatidylinositol 4,5-bisphosphate to form
phosphatidylinositol 3,4,5-trisphosphate [PtdIns(3,4,5)P3], to
which multiple pleckstrin homology domain-containing
proteins, such as PLCc2 itself, Tec family kinases required
for PLCc2 activation, protein kinase B (PKB)/Akt and
3-phosphoinositide-dependent protein kinase 1 (PDK1),
which phosphorylates and activates PKB/Akt, can bind, and
become activated and mediate their functions [40,41].
In this study, we investigated the possibility that PECAM-1
regulates the formation of the LAT–Gab1–p85 signaling
complexes and the potential effect of such interactions on
GPVI-mediated platelet activation in platelets. We demon-
strate that PECAM-1 interferes with the formation of Gab1–
p85–SHP-2 complexes upon GPVI stimulation. These results
provide a molecular explanation for PECAM-1-mediated
inhibition of collagen-stimulated PI3K signaling, and thereby
the inhibition of platelet function.
Materials and methods
Reagents
Anti-PECAM-1 monoclonal antibody for crosslinking
(AB468) and an appropriate isotype control (AB600) were
obtained from Autogen Bioclear (Nottingham, UK), and
were dialyzed to remove azide. Goat anti-mouse IgG F(ab¢)2
fragment antibody was obtained from Sigma Chemical
(Poole, UK). Anti-PECAM-1 for immunoprecipitation
(WM59) was obtained from Serotec (Oxford, UK). Anti-
PECAM-1 for immunoblotting (C-20), anti-SHP-2 (C-18),
anti-Gab1 (H-198) and protein A/G agarose were obtained
from Santa Cruz (Autogen Bioclear, London, UK). Anti-
PI3K p85 subunit (06-195) and anti-Akt/PKBawere obtained
from Upstate Biotechnology (Dundee, UK). Anti-horserad-
ish peroxidase (HRP)-conjugated secondary antibodies were
obtained from New England Biolabs (Hitchin, UK), and
enhanced chemiluminescence reagents were obtained from
GE Healthcare (Chalfont St Giles, UK). Horm-Chemie
collagen (collagen ﬁbers from equine tendons) was obtained
from Nycomed (Munich, Germany), and collagen-related
peptide (CRP) was obtained from R. Farndale (University of
Cambridge, UK). A plasmid containing cDNA encoding a
glutathione-S-transferase (GST) fusion protein containing
the N-terminal SH2 domain of p85 (GST–p85-N-SH2) was a
gift from T. Pawson (University of Toronto, Ontario,
Canada). PECAM-1 knockout mice were provided by T.
Mak (University of Toronto, Ontario Canada). All protocols
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involving the use of animals were approved by the University
of Reading Local Ethical Review Panel and authorized by a
Home Ofﬁce licence.
Mouse platelet preparation and activation
Blood was obtained from PECAM-1 knockout and con-
trol mice via cardiac puncture after death. Blood (1 mL) was
drawn into a syringe containing acidic citrate dextrose
(100 lL;120 mM sodium citrate, 110 mM glucose, 80 mM citric
acid) as anticoagulant. Platelets were prepared from whole
blood by differential centrifugation in the presence of prosta-
cyclin (0.1 lg mL)1), resuspended in modiﬁed Tyrodes–
HEPES buffer (134 mM NaCl, 0.34 mM Na2HPO4, 2.9 mM
KCl, 12 mM NaHCO3, 20 mM HEPES, 5 mM glucose, 1 mM
MgCl2, pH 7.3) to a density of 4 · 108 cells mL)1, and rested
for 30 min at 30 C prior to experiments, as described
previously [9,42,43]. For aggregation studies, platelets were
suspended at a ﬁnal concentration of 2.5 · 108 cells mL)1, and
aggregometry was performed at 37 C in an optical platelet
aggregometer (Chrono-log Corp., Havertown, PA, USA), as
described previously [9].
Platelets from PECAM-1-deﬁcient mice were found to have
similar levels of LAT, Gab-1, p85, SHP-2 and PLCc2 as
platelets derived from wild-type mice (Fig. S1).
Human platelet preparation and activation
Washed platelets were prepared from fresh blood obtained
from aspirin-free donors by differential centrifugation, as
described previously [44], and resuspended in modiﬁed
Tyrodes–HEPES buffer to a density of 4 · 108 cells mL)1.
Aggregation studies were performed at 37 C in an optical
platelet aggregometer (Chrono-log Corp.), as described
previously [7]. For protein precipitation experiments, plate-
lets were resuspended at 8 · 108 cells mL)1 and rested for
30 min at 30 C prior to experiments. PECAM-1 signaling
was induced by antibody crosslinking with mouse monoclo-
nal antibody AB468 (1 lg mL)1) and goat anti-mouse IgG
(30 lg mL)1) for 5 min prior to agonist stimulation, as
reported previously [7]. Mouse IgG antibody AB600
(1 lg mL)1) was used as the antibody control. Preincubation
with IV.3 F(ab¢) fragments, to block the low-afﬁnity receptor
for IgG FccRIIA, did not alter the inhibitory effect of
PECAM-1 crosslinking [45]. Stimulation of platelets with
collagen (25 lg mL)1) or with crosslinking PECAM-1 anti-
bodies in the presence of EGTA (1 mM) to prevent aggrega-
tion was performed at 37 C in an optical platelet
aggregometer (Chrono-log Corp.) with continuous stirring
at 1200 r.p.m.. Informed consent from all human subjects
donating blood was obtained, and procedures were approved
by the University of Reading Research Ethics Committee.
Immunoprecipitation and immunoblotting
For protein precipitation assays, platelets were suspended in
buffer containing 1 mM EGTA, 10 lM indomethacin and
2 U mL–1 apyrase to prevent platelet aggregation, release of
thromboxane A2, and the secondary effects of secreted ADP,
respectively. Immunoprecipitation, sodium dodecylsulfate
polyacrylamide gel electrophoresis (SDS-PAGE) and immuno-
blotting onto poly(vinylidine diﬂuoride) (PVDF) membranes
were performed with the use of standard techniques [7,43].
Normal IgG control was added to our immunoprecipitation
experiments, and showed no effect on the interactions revealed
in this study (Fig. S3). Quantiﬁcation was performed following
chemiﬂuorescence detection with TYPHOON FLUORESCENCE
IMAGING software (GE Healthcare).
Far-western blotting
GST–p85-N-SH2 was prepared as described previously [39].
SHP-2 immunoprecipitates from control or collagen-stimu-
lated platelets were resolved by SDS-PAGE, transferred to
PVDF membranes, blocked with bovine serum albumin
protease-free solution, and incubated for 3 h with GST–p85-
N-SH2 (10 lg mL)1), followed by anti-GST antibody
(1 : 1000). Blots were washed and incubated for 2 h with
HRP-conjugated anti-goat IgG antibody (1 : 8000), and
signals were detected with a ﬂuorescence imager (Typhoon;
GE Healthcare).
Statistical analysis
Determination of statistical signiﬁcance was performed using
Students paired t-test. Results are expressed as means ± stan-
dard errors of the mean.
Results
SHP-2 and p85 (PI3K) associate with PECAM-1 upon PECAM-
1 or GPVI stimulation
PECAM-1 tyrosine phosphorylation and subsequent activa-
tion of signaling molecules is stimulated following PECAM-1
clustering (antibody or homophilic ligation) or following
platelet activation [6,7]. Phosphorylation of PECAM-1 is
associated with the inhibition of platelet function (Fig. 1A,B),
as well as secretion and adhesion responses [6,7,9]. The
activation of PECAM-1 signaling is also stimulated down-
stream of platelet activation, and has been proposed to
represent a negative feedback mechanism [6,7]. The association
of PECAM-1 with SHP-2 has been described previously, and
shown to be mediated by the SH2 domains of this phosphatase
[23,24,28,29]. In order to determine the kinetics and extent of
SHP-2 recruitment by PECAM-1 following crosslinking of
PECAM-1 orGPVI stimulation with collagen, human platelets
were stimulated for 45 s, 1 min 30 s and 3 min, in the presence
of EGTA (1 mM), apyrase (2 U mL)1) and indomethacin
(10 lM) to prevent aggregation and ensure the study of primary
signaling events. The level of SHP-2 associated with immuno-
precipitated PECAM-1wasmeasured by immunoblot analysis.
The extent of association between PECAM-1 and SHP-2 was
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Fig. 1. Stimulation of platelet endothelial cell adhesion molecule-1 (PECAM-1) signaling results in recruitment of phosphatidylinositol 3-kinase (PI3K).
Washed human platelets were incubated with antibody speciﬁc for PECAM-1 crosslinking (XL) or isotype control prior to stimulation with collagen-
related peptide (0.5 lg mL)1) for 90 s (A), or wild-type and PECAM-1-deﬁcient mouse platelets were stimulated with collagen (2.5 lg mL)1) (B) and
aggregation wasmeasured under constant stirring conditions at 37 C.Washed human platelets were treated with EGTA (1 mM), apyrase (2 U mL)1) and
indomethacin (10 lM) prior to stimulation of PECAM-1 by antibody crosslinking (C, E) or with collagen (D, F) for 45, 90 and 180 s. (C, D) Levels of
Src homology 2 domain-containing protein tyrosine phosphatase-2 (SHP-2) associated with PECAM-1 were detected before equivalent protein loading
was veriﬁed by reprobing for PECAM-1. Levels of p85 subunit of PI3K associated with PECAM-1 detected after stimulation with glycoprotein VI agonist
collagen (25 lg mL)1) (E) or antibody speciﬁc for PECAM-1 crosslinking (1 lg mL)1) (F). Equivalent protein loading was veriﬁed by reprobing
for PECAM-1. Immunoblots were visualized by ﬂuorescence imaging, quantiﬁed, and normalized for protein loading. Numerical data represent the
percentage change of PECAM-1–SHP-2 association in stimulated samples as compared with control (mean ± standard error of the mean; n = 4). t-test:
*P £ 0.05, **P £ 0.01, ***P £ 0.001. IP, immunoprecipitation.
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dependent on the duration of stimulation, and was propor-
tional to the increase in the level of tyrosine phophorylation of
SHP-2 (Fig. 1C,D; Fig. S2). Changes in tyrosine phosphory-
lation, SHP-2 binding and PECAM-1 binding were detected at
early time points (detectable at 45 s in Fig. S2) and continued
to rise for 3 min. Under the conditions used, similar kinetics for
PECAM-1–SHP-2– interactions were observed for PECAM-1
crosslinking and stimulation of platelets with collagen. In
subsequent experiments, a time point of 90 s was chosen to
ensure that quantiﬁcation of association could be reliably
measured with this approach.
To explore the possibility that components of the activatory
GPVI pathway interact with PECAM-1, we investigated the
potential association between the p85 subunit of PI3K and
PECAM-1 following PECAM-1 or GPVI stimulation. Human
platelets were incubated with or without crosslinking with
an antibody speciﬁc for PECAM-1 for 90 s, as described in
Materials andmethods. The p85 subunit of PI3Kwas found to
associate with PECAM-1, and the level of this association was
increased signiﬁcantly upon stimulation of either PECAM-1 or
GPVI signaling (Fig. 1E,F).
p85 associates with SHP-2 upon PECAM-1 crosslinking or
GPVI stimulation
Previousstudies inothercellmodelshavesuggestedthat theSH2
domains of p85 direct the interaction of the PI3K complexwith
activated growth factor receptors and signaling intermediate
moleculessuchSHP-2,Gab1,Grb-2-associatedbindingprotein-
2, Grb2, and SHIP [38]. Given the role of PECAM-1 in the
negative regulation of platelet function and the recruitment of
SHP-2 to this ITIM-containing receptor, we investigated
whether the p85 subunit of PI3K associates with SHP-2 upon
PECAM-1 crosslinking or GPVI stimulation. As shown in
Fig. 2A,B, SHP-2 was immunoprecipitated from the lysates of
resting platelets and following stimulation of PECAM-1 and
GPVI signaling. Low levels of p85 were found to be present in
SHP-2immunoprecipitatesfromunstimulatedplatelets,andthis
association was increased notably following stimulation of
PECAM-1 or activation of platelets with collagen. In order to
exploreapotentialdirect interactionbetweenSHP-2andthep85
subunitofPI3K,weusedGST–p85-N-SH2 in far-westernblots.
Restingandcollagen-stimulated sampleswere lysed, andSHP-2
was immunoprecipitated. Immunoprecipitates were separated
by SDS-PAGE and transferred to PVDF membranes. After
incubation with GST–p85-N-SH2 or GST alone (control), the
presenceofboundfusionproteinwasdetectedwithananti-GST
antibodyandchemiﬂuorescencedetection.Anincrease inGST–
p85-N-SH2 binding to immunoprecipitated SHP-2 following
GPVI stimulation (Fig. 2C) suggested that the p85 subunit of
PI3K is capable of binding directly to SHP-2.
PECAM-1 modulates SHP-2–p85 association
As SHP-2 is capable of binding p85 directly, it is possible that
PECAM-1 (or binding of PECAM-1 to SHP-2) drives this
association.We therefore evaluated the interaction between p85
and SHP-2 in whole platelet lysates from control (wild-type)
and PECAM-1-deﬁcient platelets stimulated with collagen.
Substantially lower levels of collagen-stimulated SHP-2–p85
association were detected in PECAM-1-deﬁcient platelets than
in control platelets (Fig. 2D). These data strongly indicate that
PECAM-1 modulates SHP-2–p85 association.
PECAM-1 signaling destabilizes a collagen-stimulated Gab1–
p85 complex
In different cell types, Gab1 has been shown to contain a
number of different docking sites that mediate independent
interactions with SH2 domain-containing proteins such as
SHP-2 and the p85 subunit of PI3K. The formation of these
complexes is involved in signaling events mediated by cytokine
and tyrosine kinase receptors [36,37]. Given our ﬁnding that, in
human platelets, SHP-2 interacts directly with p85 in a manner
that depends on the presence of PECAM-1, we hypothesized
that PECAM-1 may bind to SHP-2–p85 complexes and
interfere with the ability of either of these molecules to bind
to Gab1. To test this hypothesis, we investigated the effect of
PECAM-1 crosslinking or PECAM-1 deﬁciency on the ability
of SHP-2 and p85 to interact with Gab1 in GPVI-activated
platelets. PECAM-1 crosslinking had no effect on the levels
of association of either SHP-2 (Fig. 3A) or p85 (Fig. 3B)
withGab1 in unstimulated platelets.We found that the levels of
association of SHP-2 and p85 with Gab1 in Gab1 immuno-
precipitates, which are low in resting human platelets, increased
upon stimulation of platelets with collagen (Fig. 3C,D).
Gab1–SHP-2 interactions were also found to be increased in
SHP-2 immunoprecipitates (Fig. S3F). The effect of PECAM-1
on levels of association of p85 or SHP-2 with Gab1 was
investigated with mouse platelets deﬁcient in PECAM-1.
Signiﬁcantly higher levels of association of SHP-2 (Fig. 3E)
or p85 (Fig. 3F) with Gab1 were observed in collagen-
stimulated platelets derived from PECAM-1-deﬁcient mice
than in those fromwild-typemice.On thebasis of theseﬁndings,
we conclude that PECAM-1 competes with Gab1 for associ-
ation with SHP-2 in GPVI-stimulated platelets. Furthermore,
the ability of PECAM-1-associated SHP-2 to complex with the
p85 subunit of PI3K limits the amount of p85 available to bind
to Gab1 downstream of GPVI stimulation.
LAT-mediated PI3K signaling is modulated by PECAM-1
Upon GPVI stimulation, LAT forms a platform for the
assembly of a signaling complex that includes PI3K and other
downstream molecules, which results in the activation of PI3K
signaling [39,40,46].
On the basis of our ﬁnding that PECAM-1–SHP-2–p85
complex formation limits the amount of p85 available to Gab1
in GPVI-stimulated platelets, we hypothesized that PECAM-1
would also affect the assembly of the LAT signalosome. To test
this hypothesis, the effect of PECAM-1 on interactions between
LAT and p85 was investigated in control and PECAM-1-
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deﬁcient mouse platelets following stimulation with collagen.
We found that the absence of PECAM-1 was associated with a
signiﬁcant increase in the levels of interaction between LAT
and p85 (Fig. 4A). Consistent with this and increased levels of
PI3K signaling in the absence of PECAM-1, collagen-stimu-
lated PLCc2 tyrosine phosphorylation was also found to be
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Fig. 2. Platelet endothelial cell adhesionmolecule-1 (PECAM-1) regulates the association of p85 with SHP-2.Washed human platelets (A, B) and platelets
derived from PECAM-1-deﬁcient and wild-type (WT) mice (D) were treated with EGTA (1 mM), apyrase (2 U mL)1) and indomethacin (10 lM) prior to
PECAM-1 stimulation by antibody crosslinking (XL) (A) or stimulation with collagen for 90 s (B, D). The levels of p85 associated with SHP-2 were
detected before equivalent protein loading was veriﬁed by reprobing for Src homology 2 domain-containing protein tyrosine phosphatase-2 (SHP-2).
(C) Far-western blotting for SHP-2–p85 interaction was performed on lysates of cells stimulated with collagen (25 lg mL)1) for 90 s, resolved by sodium
dodecylsulfate polyacrylamide gel electrophoresis and transferred to poly(vinylidine diﬂuoride) membranes. The membranes were incubated with
glutathione-S-transferase (GST) fusion protein containing the N-terminal SH2 domain of p85 (GST–p85-N-SH2) or GST control, followed by anti-GST
and secondary antibodies. Blots were washed and incubated for 2 h with horseradish peroxidase-conjugated anti-goat IgG antibody (1 : 8000), and
signals were detected by chemiﬂuorescence. Numerical data represent the percentage change of SHP-2–p85 association in stimulated samples as compared
with the control (mean ± standard error of the mean; n = 4). t-test: **P £ 0.01 and ***P £ 0.001. IP, immunoprecipitation.
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increased (Fig. 4B). These results indicate that PECAM-1
modulates the assembly of the LAT signalosome, which is
consistent with the regulation of PI3K signaling leading
to reductions in the PLCc2 functions of calcium regulation
and a-granule secretion [6,7,45]. To further substantiate this
model, and also in human platelets, the effect of stimulation of
PECAM-1 on GPVI-mediated recruitment of PI3K to LAT
was tested. For these experiments, the GPVI-speciﬁc agonist
CRP was used, because, with the combinations of antibodies
present, this allowed reliable quantiﬁcation. The levels of LAT-
associated p85 were determined in resting and collagen-
stimulated human platelets. As shown in Fig. 4C, low levels
of p85 were found to be present in LAT immunoprecipitates
from resting platelets, and this association was increased
signiﬁcantly following stimulation of platelets with CRP. In
order to explore whether this association would be affected by
PECAM-1 downstream signaling on GPVI signaling, levels of
LAT-associated p85 were determined upon stimulation of
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Fig. 3. The adaptor proteinGrb-2-associated binding protein-1 (Gab1) associates with Src homology 2 domain-containing protein tyrosine phosphatase-2
(SHP-2) and phosphatidylinositol 3-kinase on platelet activation. These associations are enhanced in the absence of platelet endothelial cell adhesion
molecule-1 (PECAM-1). Gab1 was immunoprecipitated fromwashed human platelets and platelets derived from PECAM-1-deﬁcient and wild-type (WT)
mice following stimulation of PECAM-1 signaling by antibody crosslinking (XL) (A, B) or collagen (C–F) for 90 s. Proteins were separated by sodium
dodecylsulfate polyacrylamide gel electrophoresis and immunoblotted to detect SHP-2 (A, C, E) and p85 (B, D, F). Numerical data represent the
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PECAM-1 following GPVI-mediated activation with CRP.
The levels of p85 associated with LAT decreased signiﬁcantly
when PECAM-1 was stimulated by crosslinking prior to CRP
stimulation (Fig. 4D). To conﬁrm that this resulted in dimin-
ished PI3K signaling, we investigated the effect of PECAM-1
crosslinking on PKB/Akt activation, which is a downstream
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consequenceofrecruitmentofPI3KtoLAT, inGPVI-activated
human platelets. PKB/Akt is activated by PDK1-mediated
phosphorylation of Ser473; therefore, PKB/Akt activationwas
measuredby immunoblot analysiswith an antibody speciﬁc for
the phosphorylated form of Ser473 (pSer473). We found that
PECAM-1 crosslinking resulted in inhibition of GPVI-stimu-
lated PKB/Akt Ser473 phosphorylation (Fig. 4E). PECAM-1
crosslinking antibody alone did not affect PKB/Akt phosphor-
ylation. These results indicate that collagen-stimulated PI3K
activation, which is dependent on recruitment of p85 toLAT in
responsetoGPVIsignaling, isnegativelyregulatedbyPECAM-
1 in human platelets. On the basis of these results, we propose
that PECAM-1-mediated inhibition ofGPVI-dependent plate-
letresponsesresults,at least inpart, fromrecruitmentofSHP-2–
p85 complexes to tyrosine-phosphorylated PECAM-1, which
destabilizes the PI3K association with the activatory signaling
molecules Gab1 andLAT.
Discussion
A number of recent studies have shown that the scaffolding
adaptor protein Gab1 is critical for signaling by a number of
receptor tyrosine kinases, cytokines, and antigen receptors [38].
Tyrosine-phosphorylated Gab1 provides docking sites for
multiple SH2 domain-containing signaling molecules, such as
SHP-2, the p85 regulatory subunit of PI3K, Crk, and PLCc,
which transduce signals following cytokine receptor stimulation
[37]. One of these binding partners, SHP-2, which is able to
dephosphorylate a number of signalingmolecules [47], has been
shown to interact with Gab1, causing dephosphorylation of
Gab1-associated phosphoproteins [47]. In platelets, it has been
found that Gab1 is associated with SHP-2 and p85 in response
to thrombopoietin [48], and one possible explanation for the
role of the association of SHP-2 with Gab1 is that this
associationmay inﬂuence the interaction betweenGab1 and the
p85 subunit of PI3K, therefore affecting downstream signaling.
Our working model (Fig. 5) shows that the activation of
platelets results in PECAM-1 phosphorylation and signaling,
providing negative feedback to activation pathways. Collagen
stimulation of platelets results in the formation of a complex
between PI3K and the adaptor protein Gab1, which also binds
to LAT, forming a signaling complex. Gab1 also interacts with
SHP-2, another component capable of joining this complex, in
collagen-stimulated platelets, and this interaction is enhanced
in the absence of PECAM-1 signaling. The stimulation of
PECAM-1 results in the recruitment of p85 to PECAM-1, and
enhances the ability of SHP-2 to interact with p85. The ability
in vitro of SHP-2 to directly interact with p85 supports the
notion that the interaction of p85 with PECAM-1 is mediated
indirectly by the phosphatase. Furthermore, the substantial
reduction in the interaction between SHP-2 and p85 in the
absence of PECAM-1 suggests that PECAM-1 controls this
association. Consistent with what has been found for other cell
types [38], our model highlights the ability of PECAM-1 to
modulate the assembly of the LAT signalosome, where
PECAM-1 activation and SHP-2 recruitment result in dimin-
ished association of the p85 subunit of PI3K with Gab1 and
LAT, moving p85 from a substrate-rich to a substrate-poor
environment (80% of PECAM-1 is excluded from lipid rafts)
[49]. This would lead to a redistribution of p85 from LAT-
containing lipid raft compartments to PECAM-1 signaling
complexes, causing a reduction in collagen-mediated signaling
through relocation of the enzyme away from the activated
collagen receptor complex.
In platelet activation, LAT forms a platform for the
assembly of a signaling complex that includes PLCc2, which
in turn becomes tyrosine-phosphorylated. PI3K is also
recruited and, through the generation of PtdIns(3,4,5)P3,
inﬂuences the recruitment and activation of PLCc2, which
liberates the second messengers 1,2-diacylglycerol and inositol
1,4,5-trisphosphate [39,40]. The formation of these molecules is
responsible for the mobilization of calcium from intracellular
stores and activation of isoforms of protein kinase C, leading
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Fig. 5. Working model for the modulation of collagen-stimulated
phosphatidylinositol 3-kinase (PI3K) signaling and platelet function by
platelet endothelial cell adhesion molecule-1 (PECAM-1). Homophilic
ligand binding or clustering of PECAM-1 or glycoprotein (GP)VI
activation by collagen results in stimulation of tyrosine phosphorylation of
the immunoreceptor tyrosine-based inhibitory motifs present in the cyto-
plasmic tail of PECAM-1. This results in the recruitment and activation of
the tyrosine phosphatase Src homology 2 domain-containing protein
tyrosine phosphatase-2 (SHP-2). Collagen stimulation of platelets results
in the formation of a complex between PI3K and the adaptor protein
Grb-2-associated binding protein-1 (Gab1), which also binds to linker for
activation of T cells (LAT), forming a signaling complex. SHP-2 is also
capable of joining this complex, an interaction that is enhanced in the
absence of PECAM-1 signaling. The stimulation of PECAM-1 results in
the recruitment of p85 to bind to PECAM-1. The ability in vitro of SHP-2
to directly interact with p85 suggests that the interaction of p85 and
PECAM-1 is mediated indirectly by the phosphatase. Indeed, the
interaction between SHP-2 and p85 is dramatically reduced in the absence
of PECAM-1, suggesting that PECAM-1 controls this interaction.
Consistent with studies in another cell types where SHP-2 disrupts Gab1
and p85 interactions, through dephosphorylation of a tyrosine required for
binding, the absence of PECAM-1 results in stabilization of the interaction
between Gab1 and p85. This indicates that PECAM-1 signaling results in
the loss of PI3K from the LAT signalosome and reduced levels of PI3K
signaling. The relative redistribution of p85 from the LAT signalosome
may be correlated with the inhibition of PI3K signaling. This provides a
mechanism by which the activation of PECAM-1 results in negative
feedback to activation pathways. GEM, glycolipid-enriched membrane;
Syk, spleen tyrosine kinase.
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to secretion and aggregation. PI3K activity also results in the
regulation of PKB, which is important for platelet function and
thrombus formation [39,41]. We recently demonstrated that
PECAM-1 signaling is capable of inhibiting activatory signal-
ing stimulated by ADP and thrombin [45], suggesting that
PECAM-1 may control a broad inhibitory mechanism in these
cells. This potential has been also reported for another platelet
ITIM receptor, G6B [50]. As LAT and its role in platelet
signaling is restricted to ITAM receptors, it is not yet fully
understood how PECAM-1 may inhibit signaling stimulated
by ADP and thrombin. One possible explanation is that
calcium mobilization following stimulation of platelets is
diminished through PECAM-1 signaling [7], indicating that
modulation of PI3K and PLCc2 may also underlie inhibition
in this context. Given the ability of PECAM-1 to modulate
signaling protein complex formation (e.g. LAT–Gab1–p85 and
SHP-2–p85) following collagen stimulation, the potential role
of PECAM-1 in regulating isoforms of PI3K that are involved
inGPVI-mediated and non-GPVI-mediated platelet activation,
such as p110b [51,52], which couples to the p85 regulatory
subunit, will be a focus of future investigations.
Our working model suggests that the relative redistribution
of p85 from lipid raft compartments may be correlated with
the inhibition of PI3K signaling and downstream effects such
as the inhibition of calcium mobilization, as we have
previously described [7]. This may represent a competitive
relationship between the LAT and PECAM-1 signalosomes,
providing a balance between ITAM-containing and ITIM-
containing receptors when they are required on the same cell.
Further work is required to understand the kinetics and
activation of these and other molecules involved in this
complex process.
Our ﬁndings indicate that PECAM-1, through regulation of
protein complex formation, modulates the subcellular locali-
zation of PI3K, thereby diminishing GPVI-stimulated PI3K
signaling.
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